Macular Degeneration Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with a specific type of wet age-related macular degeneration (wet AMD) where abnormal blood vessels have grown under the central part of your retina, with no restriction on how large the affected area is.
• Your wet AMD is considered active, meaning scans show fluid under or within the retina, and the scarred area makes up less than half of the total affected area.
• Your vision in the eye being considered is at least a certain minimum level — roughly equivalent to being able to read the 20/320 line on an eye chart (or scoring 23 letters or more on a special vision test), measured at two separate visits.
• Only one eye will be treated in this trial; if both eyes qualify, the one with worse vision will be chosen, or the doctor will decide if vision is equal in both eyes.

Who may not be able to join:

• You are unable or unwilling to follow the study schedule and attend all required appointments.
• You are currently pregnant or breastfeeding.
• You are a woman who could become pregnant and are not willing or able to use a reliable form of contraception throughout the entire study (this does not apply if you have had a surgical procedure to prevent pregnancy or have been through menopause for more than 2 years).
• You have any ongoing illness or are receiving treatment for a condition that, in the doctor's opinion, could significantly affect the study results or put you at extra risk.
• You have had a stroke or heart attack within the 3 months before signing the consent form.
• Your blood pressure is not well controlled (specifically, the top number is above 160 or the bottom number is above 100 at either of your screening visits).
• You have a known allergy or sensitivity to the study drug (aflibercept 8mg) or any of its ingredients.
• You have previously taken or are currently taking any anti-VEGF medicines by mouth, injection into a vein, or any other systemic route (for example, bevacizumab/Avastin®).
• You are currently taking, or plan to take, certain medicines known to be harmful to the eye, including chloroquine, hydroxychloroquine (Plaquenil®), deferoxamine, phenothiazines, tamoxifen, or ethambutol.
• You have used steroid medicines (by mouth, injection, or into the eye) for 30 or more days in a row within the 3 months before signing the consent form.
• You have taken part in another clinical trial and received an experimental drug within the 6 months before signing the consent form.
• You previously tried to join this same study but did not qualify at that time.

Regarding the eye being considered for treatment:

• You have an active infection or inflammation in or around the eye at either screening visit (confirm with trial site).
• You have glaucoma that is not well controlled, with eye pressure of 30 mmHg or higher even with treatment.
• You have abnormal blood vessel growth on the iris or a type of glaucoma caused by these new blood vessels.
• The scans needed to assess your retina cannot be taken with enough clarity for the study team to analyse them.
• You have had eye surgery (including a certain type of laser capsule procedure) within 2 months before signing the consent form, or you expect to need eye surgery within 6 months after signing.
• You have certain other eye conditions at your screening visits, such as a significant cataract, a missing or artificial lens, a specific condition affecting the lens (pseudoexfoliation), a large bleed in the eye, a detached retina, diabetic eye disease, or abnormal blood vessel growth caused by something other than wet AMD.
• There is permanent damage in the central area of your retina that, in the doctor's opinion, means your vision is unlikely to improve even with treatment.
• There is a large bleed (1 disc diameter or more) directly over the central part of your retina at your screening visits.
• The eye being considered has ever previously been treated with an anti-VEGF injection, a steroid injection into the eye, photodynamic therapy (a light-based treatment), or any other retinal laser treatment.

Important: Always verify eligibility with the trial site directly before applying.